BIOVIE INC. annual report, FY2015

Business context and reporting period

The supplied filing is NanoAntibiotics, Inc.’s Form 10-K for the fiscal year ended June 30, 2015—not a BioVie Inc. filing or a 2014 Q4 report. The company describes itself as an early-stage biotechnology developer of antibiotics targeting drug-resistant bacteria. Its candidates had been tested only in cell-based assays; no animal efficacy, pharmacokinetic, or toxicity studies had been conducted. Research and development was on hold while the company pursued additional technology licenses.

Financial results and liquidity

With no revenue or cost of goods sold, gross margin is not meaningful. R&D expense was $4,196 versus $49,419. The balance sheet showed total assets of $269,481, including $267,481 cash, and a stockholders’ deficit of $54,119. Current liabilities comprised $322,950 accrued payroll and $650 accounts payable; the filing reports no interest expense or financing cash flow. Working capital was negative $54,119.

Changes versus prior year

Net loss narrowed by about 28%, and operating cash use declined by about 62%. Operating expenses fell by about 28%, driven in part by lower R&D and professional fees; payroll expense remained broadly level. Cash declined by $65,383. Accrued payroll doubled to $322,950. No shares were issued during FY2015, and common shares outstanding remained 87.21 million.

Outlook, risks, and unusual items

• Management said existing cash would not cover the next 12 months and estimated a need for approximately $1 million in additional net financing. Its proposed 12-month budget was $750,000 for R&D and licensing, $50,000 for corporate overhead, $50,000 for capital costs, and $150,000 for staffing. Funding was not committed.
• The auditor and management cited substantial doubt about the company’s ability to continue as a going concern. Without financing, management may reduce or halt development, pursue licensing or strategic transactions, or cease operations.
• There were no approved products, revenues, or filed patent applications. Further development depends on licensing, funding, preclinical work, clinical trials, and regulatory approval; success is uncertain.
• Disclosure controls and internal control over financial reporting were reported ineffective. Management cited insufficient formal controls, lack of segregation of duties, and no independent audit committee chair. The auditor did not audit internal control effectiveness.
• The company’s compounds and related studies originated at Kard Scientific, controlled by its president; the company recorded the transferred rights at zero historical cost. The filing also notes potential conflicts of interest and no policy for addressing them.
• The company had a five-year office lease with aggregate payments of $21,420 and an employment agreement providing the CEO/CFO a $150,000 annual salary, which continued at that rate pending a new agreement.
• Shares traded OTC under NNAB. The filing warns of limited liquidity, potential dilution, concentrated ownership, and no expected dividends.

Important facts for investors to verify

1. Confirm the issuer and period: the supplied document is for NanoAntibiotics, Inc., FY ended June 30, 2015, despite the request metadata naming BioVie Inc. and 2014 Q4.
2. Verify the reported financing need, cash runway, and status of any financing or licensing arrangements after year-end.
3. Check the accrued payroll balance, employment-agreement terms, and any subsequent payments or settlements.
4. Review subsequent progress on animal studies, licensing, patent filings, and the paused R&D program.
5. Confirm the filing’s reported audit date: the auditor’s report is dated September 21, 2014, although it covers FY2015 financial statements; this appears inconsistent with the report period and should be checked against the original filing.
6. Review the original financial statements for presentation issues: the cash-flow statement labels both comparative columns “2015,” although the figures correspond to FY2015 and FY2014.